Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies
暂无分享,去创建一个
M. Phillip | S. Heller | C. Mathieu | R. Bergenstal | E. Araki | N. Iqbal | P. Di Bartolo | P. Dandona | N. Arya | M. Scheerer | John Xu | M. Lind | L. Hansen | F. Thoren | Nikita Arya | F. Thorén | Lars Hansen
[1] A. Salsali. Review for "Long‐Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: Pooled 52‐Week Outcomes from the DEPICT‐1 and ‐2 Studies" , 2020 .
[2] O. Tomonaga,et al. Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial , 2019, Diabetes, obesity & metabolism.
[3] B. Zinman,et al. Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol , 2019, Diabetes, obesity & metabolism.
[4] I. Dicembrini,et al. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials , 2019, Acta Diabetologica.
[5] S. Edelman,et al. Sodium‐glucose co‐transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials , 2019, Diabetes, obesity & metabolism.
[6] T. Oron,et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors , 2019, Diabetes Care.
[7] M. Phillip,et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study , 2018, Diabetes Care.
[8] B. Zinman,et al. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials , 2018, Diabetes Care.
[9] S. Garg,et al. Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. , 2018, Diabetes technology & therapeutics.
[10] C. Mathieu,et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial , 2018, Diabetes Care.
[11] V. Vallon,et al. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus , 2018, Drugs.
[12] S. PatelNeha,et al. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. , 2017 .
[13] M. Phillip,et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.
[14] O. Hamdy,et al. Weight Management in Patients with Type 1 Diabetes and Obesity , 2017, Current Diabetes Reports.
[15] K. Brodovicz,et al. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review , 2017, BMJ Open.
[16] R. Schmieder,et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation , 2017, Cardiovascular Diabetology.
[17] W. Tamborlane,et al. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. , 2017, Diabetes technology & therapeutics.
[18] M. Matsuhisa,et al. Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus , 2017, Advances in Therapy.
[19] S. Ito,et al. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study , 2016, Journal of clinical medicine research.
[20] R. Henry,et al. Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes , 2015, Diabetes Care.
[21] I. Hirsch,et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.
[22] David M Maahs,et al. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.
[23] B. Zinman,et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.
[24] A. Rosengren,et al. Glycemic control and excess mortality in type 1 diabetes. , 2014, The New England journal of medicine.
[25] B. Zinman,et al. Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association , 2014, Diabetes Care.
[26] D. Nathan,et al. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview , 2013, Diabetes Care.
[27] Simon R. Heller,et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.
[28] V. Woo,et al. Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin , 2012, Annals of Internal Medicine.
[29] J. Kullberg,et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.
[30] J. N. Fisher,et al. Hyperglycemic Crises in Adult Patients With Diabetes , 2009, Diabetes Care.
[31] P. Norwood,et al. A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers , 2009, Diabetes Care.
[32] B. Kestenbaum,et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. , 2008, Archives of internal medicine.
[33] D. Gordin,et al. Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes , 2007, Diabetologia.
[34] Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. , 2005, Diabetes care.
[35] Matthew D. Davis,et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.